Table 1.
Data on AVV-mediated delivery of therapeutic genes.
| Serotype | Delivery Gene | Model | Antiepileptic Effect | Reference |
|---|---|---|---|---|
| AAV2; AAV1/2 | NPY | KA, rats | Reducing the number of seizures; reducing the duration of seizure activity | [151] |
| AAV2 | KA, rats | Increase in the latent period of limbic convulsive activity | [160] | |
| AVV1/2 | Electrical stimulation, rats | Reducing the frequency of seizures; decrease in the progression of seizures by 80% | [152] | |
| AAV1 | KA, rats | Reducing the number of seizures by 55%; reducing the duration of ictal activity | [153] | |
| AAV1/2 | KA, rats | Preventing the progression of the frequency of seizures by 57.5 ± 19.3%; reducing the duration of seizure activity | [162] | |
| AAV1/2 | GAERS GGE, rats | Reducing the duration of seizure activity; reducing the number of seizures | [163] | |
| AAV1 | KA, rats | Reducing the severity of seizures; increase in the latent time; decrease in the frequency and total time of seizure activity; SRS suppression | [164] | |
| AAV1, AAV2, AAV8 | KA, rats + resected human hippocampus | AAV1 reduces the time spent on motor seizures and increases the latency period to SE | [166] | |
| AAV2 | Y2 | Kindling, KA, rats | Reduction of the cumulative degree of seizures; reducing the number of severe grade 4–5 seizures and increasing the amount of stimulation needed to achieve grade 3 or 4–5 seizures | [161] |
| AAV2 | GAL | KA, rats, HEK 293 cells | Decrease in in vivo sensitivity to focal seizures and prevention of hilar cell death caused by kainic acid | [181] |
| AAV2 | KA, rats, HEK 293 cells | Increase in the threshold of excitability; reduction of neuronal death | [182] | |
| AAV2 | KA, Kindling, rats | Suppression of limbic seizures; increase in the stimulation current required to induce limbic convulsive activity | [183] | |
| AAV1/2 | HOMER 1 | Electrical stimulation, rats | Suppression of SSLSE | [230] |
| AAV2 | GABRA4 | Electrical stimulation, rats | Suppression of SSLSE | [214] |
| AAV2 | GDNF | Kindling, rats | Suppression of SSLSE; increased survival after SE | [219] |
| AAV1/2 | CB1 | KA, mice | Reducing the severity of seizures; protection from excitotoxicity and neuronal death | [216] |
| AAV2 | Nrf2 | Lithium-pilocarpine model, mice | Decrease in microglia activation; the ratio between astrocytes/neurons and activated microglia/neurons was significantly lower | [229] |
| AAV9 | EAAT2 | KA, rats | There were no differences in the total duration of seizures between the animals that were injected with the EAAT2, GS vector, and the control vector | [242] |
| GS | ||||
| AAV1 | Dyn | KA, electrical stimulation, rats, mice | Suppression of seizures; the disappearance of generalized seizures | [184] |
| AAV2 | NL2 | Models of polygenic epilepsy, mice | Significant decrease in the duration, strength and frequency of seizures was observed over a 14-week period | [217] |
| AAV9 | SCN1A | Scn1a+/−, mice, primates | Reducing the frequency, duration and severity of spontaneous seizures; reduces the sensitivity of HTS in Dravet mice | [193] |
| AAV2 | KCNN4 | 4-aminopyridine model, mice | Powerful suppression of pharmacologically induced seizures in vitro both at the level of single cells and at the level of the local field, with a decrease in peaks during ictal discharges | [215] |